REGENERON PHARMACEUTICALS INC. - COMMON STOCK

Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer

09 Sep 2025 04:00:18 By Nasdaq GlobeNewswire

Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies

08 Sep 2025 03:30:00 By Nasdaq GlobeNewswire

Regeneron Announces Updated Presentation Time for Upcoming Investor Conference

04 Sep 2025 13:05:00 By Nasdaq GlobeNewswire

Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis

26 Aug 2025 04:00:20 By Nasdaq GlobeNewswire

EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension

20 Aug 2025 08:19:54 By Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

07 Aug 2025 13:05:02 By Nasdaq GlobeNewswire

Regeneron Reports Second Quarter 2025 Financial and Operating Results

01 Aug 2025 03:30:00 By Nasdaq GlobeNewswire

Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation

24 Jul 2025 04:30:00 By Nasdaq GlobeNewswire

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

02 Jul 2025 08:00:36 By Nasdaq GlobeNewswire

Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025

26 Jun 2025 13:05:00 By Nasdaq GlobeNewswire

Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

24 Jun 2025 04:30:00 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

19 Jun 2025 22:00:53 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

15 Jun 2025 08:21:00 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

07 Jun 2025 15:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

05 Jun 2025 06:50:06 By NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

02 Jun 2025 07:03:28 By NetDania Notify

Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist

02 Jun 2025 04:05:33 By Nasdaq GlobeNewswire

Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass

02 Jun 2025 04:00:00 By Nasdaq GlobeNewswire

Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing

31 May 2025 05:04:38 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

30 May 2025 06:45:02 By NetDania Notify